Validated animal models are required as bridging tools to assess the utility of novel therapies and potential microbiologic outcomes. Herein, we utilized uropathogenic ESBL/non-ESBL E. coli in the neutropenic murine cUTI model with humanized exposures of cefepime, ertapenem, and levofloxacin to assess its translation value to human outcomes. Our data support the translational utility of this murine model to cUTI in man as humanized exposures produced microbiologic outcomes consistent with phenotypic profiles of the organisms.
http://ift.tt/2xsV78N
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.